Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
Shiraz University of Medical Sciences
Modality
UNKNOWN
Development Phase
Early Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02289235CT.gov Effects of Ginger on Nonalcoholic Fatty Liver Disease in T2DM | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fatty Liver Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ginger (this asset) | Shiraz University of Medical Sciences | Early P1 | CC · 41 |
| Metformin | Leiden University Medical Center | P4 | BBB |
| Alpha Tocopherol | Yuen Kah Hay | P4 | BB |
| Raltegravir | Helsinki University Central Hospital | P4 | BB |
| Rilpivirine | Fundacion SEIMC-GESIDA | P4 | BB |
| Dolutegravir | Fundacion SEIMC-GESIDA | P4 | BB |
| Empagliflozin | Seoul National University Bundang Hospital | P4 | BB |
| Pioglitazone | Seoul National University Bundang Hospital | P4 | BB |
| Liraglutide | Leiden University Medical Center | P4 | BB |
+42 more in the Fatty Liver Disease cohort
Other indications for Ginger
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Vertebral Column Disorder | — | P4 | BB · 68 |
| Cancer Of Unknown Primary Site | — | P2 | B · 57 |
| Neuralgia | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ginger in Fatty Liver Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ginger-fatty-liver-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →